Schedule of Investments (unaudited) March 31, 2023 | BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Common Stocks | ||||||||
Biotechnology — 22.0% | ||||||||
AbbVie, Inc. | 111,783 | $ | 17,814,857 | |||||
Affinivax, Inc., (Acquired 08/18/22, Cost: $0)(a)(b) | 6,331 | 83,126 | ||||||
Alkermes PLC(c) | 32,331 | 911,411 | ||||||
Alnylam Pharmaceuticals, Inc.(c) | 15,553 | 3,115,577 | ||||||
Amgen, Inc.(d) | 67,355 | 16,283,071 | ||||||
Apellis Pharmaceuticals, Inc.(c) | 13,695 | 903,322 | ||||||
Arcutis Biotherapeutics, Inc.(c) | 42,854 | 471,394 | ||||||
Argenx SE, ADR(c) | 7,121 | 2,653,142 | ||||||
Biogen, Inc.(c) | 21,312 | 5,925,375 | ||||||
BioMarin Pharmaceutical, Inc.(c) | 34,910 | 3,394,648 | ||||||
Biomea Fusion, Inc.(c) | 17,544 | 544,039 | ||||||
BioNTech SE, ADR | 10,000 | 1,245,700 | ||||||
Blueprint Medicines Corp.(c) | 26,725 | 1,202,358 | ||||||
Cellarity, Inc., Series B, (Acquired 01/15/21, | 44,167 | 174,460 | ||||||
Cerevel Therapeutics Holdings, Inc.(c) | 16,785 | 409,386 | ||||||
CureVac NV(c)(e) | 20,488 | 142,801 | ||||||
Decibel Therapeutics, Inc.(c) | 46,884 | 141,590 | ||||||
Design Therapeutics, Inc.(c) | 13,967 | 80,590 | ||||||
Enanta Pharmaceuticals, Inc.(c) | 3,150 | 127,386 | ||||||
Exact Sciences Corp.(c) | 16,381 | 1,110,796 | ||||||
Frequency Therapeutics, Inc.(c) | 28,060 | 14,114 | ||||||
Genmab A/S(c) | 2,498 | 944,257 | ||||||
Genmab A/S, ADR(c)(e) | 16,911 | 638,559 | ||||||
Gilead Sciences, Inc. | 172,670 | 14,326,430 | ||||||
Horizon Therapeutics PLC(c) | 7,410 | 808,727 | ||||||
Immuneering Corp., Class A(c)(e) | 14,456 | 140,368 | ||||||
Immunocore Holdings PLC, ADR(c)(e) | 9,668 | 477,986 | ||||||
Incyte Corp.(c) | 33,358 | 2,410,783 | ||||||
Ionis Pharmaceuticals, Inc.(c) | 18,640 | 666,194 | ||||||
IVERIC bio, Inc.(c) | 12,230 | 297,556 | ||||||
Karuna Therapeutics, Inc.(c) | 1,825 | 331,493 | ||||||
Krystal Biotech, Inc.(c) | 3,135 | 250,988 | ||||||
Legend Biotech Corp., ADR(c) | 14,146 | 682,120 | ||||||
Mirati Therapeutics, Inc.(c) | 15,380 | 571,828 | ||||||
Moderna, Inc.(c) | 28,938 | 4,444,298 | ||||||
Monte Rosa Therapeutics, Inc.(c) | 28,575 | 222,599 | ||||||
Morphic Holding, Inc.(c) | 7,120 | 267,997 | ||||||
Neurocrine Biosciences, Inc.(c) | 23,254 | 2,353,770 | ||||||
Nuvalent, Inc., Class A(c) | 11,178 | 291,634 | ||||||
PMV Pharmaceuticals, Inc.(c) | 17,490 | 83,427 | ||||||
Prime Medicine, Inc.(c)(e) | 22,929 | 282,027 | ||||||
Prometheus Biosciences, Inc.(c) | 6,920 | 742,654 | ||||||
Protagonist Therapeutics, Inc.(c) | 19,310 | 444,130 | ||||||
Prothena Corp. PLC(c) | 8,734 | 423,337 | ||||||
PTC Therapeutics, Inc.(c) | 6,385 | 309,289 | ||||||
Regeneron Pharmaceuticals, Inc.(c) | 17,857 | 14,672,561 | ||||||
Revolution Medicines, Inc.(c) | 18,874 | 408,811 | ||||||
Rhythm Pharmaceuticals, Inc.(c) | 48,130 | 858,639 | ||||||
Rocket Pharmaceuticals, Inc.(c) | 17,213 | 294,859 | ||||||
Sage Therapeutics, Inc.(c) | 21,680 | 909,693 | ||||||
Sarepta Therapeutics, Inc.(c) | 18,688 | 2,575,767 | ||||||
Seagen, Inc.(c) | 20,872 | 4,225,954 | ||||||
Sigilon Therapeutics, Inc.(c) | 19,555 | 18,188 | ||||||
Tenaya Therapeutics, Inc.(c) | 25,502 | 72,681 | ||||||
TScan Therapeutics, Inc.(c) | 29,940 | 62,874 | ||||||
Ultragenyx Pharmaceutical, Inc.(c) | 6,140 | 246,214 |
Security | Shares | Value | ||||||
Biotechnology (continued) | ||||||||
Vertex Pharmaceuticals, Inc.(c)(e) | 47,119 | $ | 14,845,783 | |||||
Viking Therapeutics, Inc.(c) | 16,970 | 282,551 | ||||||
|
| |||||||
128,636,169 | ||||||||
Health Care Equipment & Supplies — 25.1% | ||||||||
Abbott Laboratories(d) | 129,731 | 13,136,561 | ||||||
Alcon, Inc. | 88,739 | 6,259,649 | ||||||
Align Technology, Inc.(c) | 3,960 | 1,323,194 | ||||||
Bausch & Lomb Corp.(c) | 75,830 | 1,320,200 | ||||||
Baxter International, Inc. | 111,827 | 4,535,703 | ||||||
Becton Dickinson and Co. | 36,070 | 8,928,768 | ||||||
Boston Scientific Corp.(c) | 432,925 | 21,659,238 | ||||||
Cooper Cos., Inc. | 12,951 | 4,835,385 | ||||||
Dexcom, Inc.(c) | 54,892 | 6,377,353 | ||||||
Edwards Lifesciences Corp.(c) | 37,566 | 3,107,835 | ||||||
Envista Holdings Corp.(c) | 21,195 | 866,452 | ||||||
GE HealthCare Technologies, Inc.(c) | 68,490 | 5,618,235 | ||||||
Glaukos Corp.(c) | 4,880 | 244,488 | ||||||
Hologic, Inc.(c) | 10,990 | 886,893 | ||||||
IDEXX Laboratories, Inc.(c) | 7,185 | 3,593,075 | ||||||
Insulet Corp.(c) | 8,555 | 2,728,703 | ||||||
Intuitive Surgical, Inc.(c) | 56,844 | 14,521,937 | ||||||
iRhythm Technologies, Inc.(c) | 2,280 | 282,788 | ||||||
Masimo Corp.(c)(e) | 8,860 | 1,635,024 | ||||||
Medtronic PLC | 137,740 | 11,104,599 | ||||||
Novocure Ltd.(c)(e) | 27,700 | 1,665,878 | ||||||
Omnicell, Inc.(c) | 6,425 | 376,955 | ||||||
Orchestra BioMed Holdings, Inc.(c)(e) | 13,696 | 268,031 | ||||||
Penumbra, Inc.(c) | 21,510 | 5,994,622 | ||||||
ResMed, Inc. | 14,439 | 3,161,997 | ||||||
STERIS PLC | 9,590 | 1,834,375 | ||||||
Stryker Corp. | 65,135 | 18,594,088 | ||||||
Zimmer Biomet Holdings, Inc. | 14,617 | 1,888,516 | ||||||
|
| |||||||
146,750,542 | ||||||||
Health Care Providers & Services — 15.1% | ||||||||
Agiliti, Inc.(c) | 40,496 | 647,126 | ||||||
AmerisourceBergen Corp. | 55,773 | 8,929,815 | ||||||
Centene Corp.(c) | 29,311 | 1,852,748 | ||||||
Cigna Group | 13,289 | 3,395,738 | ||||||
Elevance Health, Inc.(d) | 12,737 | 5,856,600 | ||||||
Encompass Health Corp. | 15,684 | 848,504 | ||||||
Guardant Health, Inc.(c) | 11,675 | 273,662 | ||||||
HCA Healthcare, Inc. | 14,645 | 3,861,594 | ||||||
Humana, Inc. | 9,185 | 4,458,950 | ||||||
McKesson Corp. | 24,550 | 8,741,028 | ||||||
Quest Diagnostics, Inc. | 40,564 | 5,738,995 | ||||||
UnitedHealth Group, Inc.(d) | 92,029 | 43,491,985 | ||||||
|
| |||||||
88,096,745 | ||||||||
Life Sciences Tools & Services — 13.3% | ||||||||
10X Genomics, Inc., Class A(c) | 9,740 | 543,395 | ||||||
Agilent Technologies, Inc. | 25,861 | 3,577,611 | ||||||
Avantor, Inc.(c) | 78,897 | 1,667,883 | ||||||
Danaher Corp. | 77,879 | 19,628,623 | ||||||
Icon PLC(c) | 8,210 | 1,753,574 | ||||||
Illumina, Inc.(c)(e) | 12,680 | 2,948,734 | ||||||
IQVIA Holdings, Inc.(c) | 26,058 | 5,182,676 | ||||||
Mettler-Toledo International, Inc.(c) | 1,055 | 1,614,371 | ||||||
Nautilus Biotechnology, Inc.(c) | 16,560 | 45,871 | ||||||
QIAGEN NV(c) | 31,011 | 1,424,335 | ||||||
Rapid Micro Biosystems, Inc., Class A(c) | 20,561 | 26,935 | ||||||
Repligen Corp.(c) | 8,190 | 1,378,868 |
1 |
|
Schedule of Investments (unaudited) (continued) March 31, 2023 | BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Life Sciences Tools & Services (continued) | ||||||||
Thermo Fisher Scientific, Inc.(f) | 50,138 | $ | 28,898,039 | |||||
Waters Corp.(c) | 12,225 | 3,785,227 | ||||||
West Pharmaceutical Services, Inc. | 15,420 | 5,342,567 | ||||||
|
| |||||||
77,818,709 | ||||||||
Pharmaceuticals — 20.8% | ||||||||
Arvinas, Inc.(c) | 15,330 | 418,816 | ||||||
AstraZeneca PLC | 41,126 | 5,698,183 | ||||||
AstraZeneca PLC, ADR | 24,607 | 1,707,972 | ||||||
Bristol-Myers Squibb Co. | 39,106 | 2,710,437 | ||||||
Catalent, Inc.(c) | 20,045 | 1,317,157 | ||||||
Daiichi Sankyo Co. Ltd. | 106,000 | 3,866,629 | ||||||
Eli Lilly and Co. | 98,033 | 33,666,493 | ||||||
Johnson & Johnson(d) | 101,374 | 15,712,970 | ||||||
Merck & Co., Inc.(d) | 236,240 | 25,133,574 | ||||||
Novo Nordisk A/S, Class B | 26,375 | 4,188,911 | ||||||
Pfizer, Inc.(d) | 206,621 | 8,430,137 | ||||||
Pliant Therapeutics, Inc.(c) | 12,594 | 335,000 | ||||||
Roche Holding AG | 6,561 | 1,874,756 | ||||||
Sanofi | 24,587 | 2,667,166 | ||||||
Structure Therapeutics, Inc.(c) | 13,208 | 314,218 | ||||||
Zoetis, Inc. | 80,144 | 13,339,167 | ||||||
|
| |||||||
121,381,586 | ||||||||
|
| |||||||
Total Common Stocks — 96.3% | 562,683,751 | |||||||
|
| |||||||
Benefical Interest (000) | ||||||||
Other Interests | ||||||||
Health Care Providers & Services — 0.0% | ||||||||
Afferent Pharmaceuticals, Inc.(a)(b)(g) | $ | 190 | 150,226 | |||||
|
| |||||||
Total Other Interests — 0.0% |
| 150,226 | ||||||
|
| |||||||
Shares | ||||||||
Preferred Securities | ||||||||
Preferred Stocks — 0.7%(a)(b) | ||||||||
Biotechnology — 0.1% | ||||||||
Goldfinch Bio, Inc., Series B, | 190,000 | 62,700 | ||||||
Laronde, Inc., Series B, | 21,100 | 531,720 | ||||||
Neurogene, Inc., Series B, | 106,790 | 260,568 | ||||||
|
| |||||||
854,988 | ||||||||
Health Care Equipment & Supplies — 0.2% | ||||||||
Exo Imaging, Inc., Series C, | 101,741 | 285,892 | ||||||
Nucleix Ltd., Series AA, | 367,395 | 1,036,054 | ||||||
Swift Health Systems, Inc., Series D, | 92,580 | 133,315 | ||||||
|
| |||||||
1,455,261 |
Security | Shares | Value | ||||||
| ||||||||
Health Care Providers & Services — 0.1% | ||||||||
Quanta Dialysis Technologies Ltd., Series D, | 4,243,029 | $ | 366,394 | |||||
|
| |||||||
Pharmaceuticals — 0.1% | ||||||||
Insitro, Inc., Series C, | 30,616 | 356,064 | ||||||
|
| |||||||
Software — 0.2% | ||||||||
Carbon Health Technologies, Inc., | 89,892 | 1,066,119 | ||||||
|
| |||||||
4,098,826 | ||||||||
|
| |||||||
Total Preferred Securities — 0.7% | 4,098,826 | |||||||
|
| |||||||
Rights | ||||||||
Health Care Equipment & Supplies — 0.0% | ||||||||
Abiomed, Inc.(a) | 14,359 | 40,062 | ||||||
|
| |||||||
Total Rights — 0.0% | 40,062 | |||||||
|
| |||||||
Warrants | ||||||||
Health Care Providers & Services — 0.0% | ||||||||
CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 07/16/25, Strike Price USD 11.50)(c) | 4,201 | 2,136 | ||||||
|
| |||||||
Pharmaceuticals — 0.0% | ||||||||
Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike Price USD 11.50)(c) | 4,050 | 486 | ||||||
|
| |||||||
Total Warrants — 0.0% | 2,622 | |||||||
|
| |||||||
Total Long-Term Investments — 97.0% |
| 566,975,487 | ||||||
|
| |||||||
Short-Term Securities | ||||||||
Money Market Funds — 4.2% | ||||||||
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.70%(h)(i) | 20,478,474 | 20,478,474 | ||||||
SL Liquidity Series, LLC, Money Market Series, 5.01%(h)(i)(j) | 3,860,355 | 3,860,355 | ||||||
|
| |||||||
Total Short-Term Securities — 4.2% |
| 24,338,829 | ||||||
|
| |||||||
Total Investments Before Options Written — 101.2% |
| 591,314,316 | ||||||
|
| |||||||
Options Written — (1.1)% |
| (5,971,233 | ) | |||||
|
| |||||||
Total Investments, Net of Options Written — 100.1% |
| 585,343,083 | ||||||
Liabilities in Excess of Other Assets — (0.1)% |
| (845,797 | ) | |||||
|
| |||||||
Net Assets — 100.0% |
| $ | 584,497,286 | |||||
|
|
(a) | Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy. |
(b) | Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $4,506,638, representing 0.8% of its net assets as of period end, and an original cost of $5,276,327. |
SCHEDULE OF INVESTMENTS | 2 |
Schedule of Investments (unaudited) (continued) March 31, 2023 | BlackRock Health Sciences Trust (BME) |
(c) | Non-income producing security. |
(d) | All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
(e) | All or a portion of this security is on loan. |
(f) | All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
(g) | Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities. |
(h) | Affiliate of the Trust. |
(i) | Annualized 7-day yield as of period end. |
(j) | All or a portion of this security was purchased with the cash collateral from loaned securities. |
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the period ended March 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
Affiliated Issuer | Value at 12/31/22 | Purchases at Cost | Proceeds from Sales | Net Realized Gain (Loss) | Change in Unrealized Appreciation (Depreciation) | Value at 03/31/23 | Shares Held at 03/31/23 | Income | Capital Gain Distributions from Underlying Funds | |||||||||||||||||||||||||||
BlackRock Liquidity Funds, T-Fund, Institutional Class | $ | 23,195,315 | $ | — | $ | (2,716,841) | (a) | $ | — | $ | — | $ | 20,478,474 | 20,478,474 | $ | 229,487 | $ | — | ||||||||||||||||||
SL Liquidity Series, LLC, Money Market Series | 675,980 | 3,184,005 | (a) | — | 1,126 | (756 | ) | 3,860,355 | 3,860,355 | 7,829 | (b) | — | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||||||
$ | 1,126 | $ | (756 | ) | $ | 24,338,829 | $ | 237,316 | $ | — | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
(a) | Represents net amount purchased (sold). |
(b) | All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||||||
Call | ||||||||||||||||||||||||||||
Avantor, Inc. | 75 | 04/03/23 | USD | 25.29 | USD | 159 | $ | — | ||||||||||||||||||||
Revolution Medicines, Inc. | 18 | 04/03/23 | USD | 26.50 | USD | 39 | — | |||||||||||||||||||||
Amgen, Inc. | 126 | 04/06/23 | USD | 240.00 | USD | 3,046 | (42,210 | ) | ||||||||||||||||||||
BioNTech SE, ADR | 38 | 04/06/23 | USD | 140.00 | USD | 473 | (380 | ) | ||||||||||||||||||||
Bristol-Myers Squibb Co. | 74 | 04/06/23 | USD | 70.00 | USD | 513 | (1,739 | ) | ||||||||||||||||||||
Centene Corp. | 111 | 04/06/23 | USD | 70.00 | USD | 702 | (1,665 | ) | ||||||||||||||||||||
Gilead Sciences, Inc. | 38 | 04/06/23 | USD | 82.00 | USD | 315 | (5,396 | ) | ||||||||||||||||||||
Intuitive Surgical, Inc. | 48 | 04/06/23 | USD | 245.00 | USD | 1,226 | (56,160 | ) | ||||||||||||||||||||
Johnson & Johnson | 18 | 04/06/23 | USD | 155.00 | USD | 279 | (2,097 | ) | ||||||||||||||||||||
Medtronic PLC | 65 | 04/06/23 | USD | 83.00 | USD | 524 | (618 | ) | ||||||||||||||||||||
Merck & Co., Inc. | 234 | 04/06/23 | USD | 109.00 | USD | 2,490 | (4,446 | ) | ||||||||||||||||||||
Moderna, Inc. | 72 | 04/06/23 | USD | 145.00 | USD | 1,106 | (68,220 | ) | ||||||||||||||||||||
UnitedHealth Group, Inc. | 65 | 04/06/23 | USD | 500.00 | USD | 3,072 | (1,625 | ) | ||||||||||||||||||||
Abbott Laboratories | 246 | 04/14/23 | USD | 107.00 | USD | 2,491 | (2,091 | ) | ||||||||||||||||||||
AbbVie, Inc. | 105 | 04/14/23 | USD | 150.00 | USD | 1,673 | (102,112 | ) | ||||||||||||||||||||
AstraZeneca PLC, ADR | 93 | 04/14/23 | USD | 67.00 | USD | 646 | (26,133 | ) | ||||||||||||||||||||
Baxter International, Inc. | 53 | 04/14/23 | USD | 41.00 | USD | 215 | (3,180 | ) | ||||||||||||||||||||
Danaher Corp. | 161 | 04/14/23 | USD | 250.00 | USD | 4,058 | (111,895 | ) | ||||||||||||||||||||
Elevance Health, Inc. | 34 | 04/14/23 | USD | 480.00 | USD | 1,563 | (7,225 | ) | ||||||||||||||||||||
Eli Lilly & Co. | 119 | 04/14/23 | USD | 335.00 | USD | 4,087 | (132,090 | ) | ||||||||||||||||||||
GE HealthCare Technologies, Inc. | 260 | 04/14/23 | USD | 80.00 | USD | 2,133 | (76,700 | ) | ||||||||||||||||||||
Gilead Sciences, Inc. | 295 | 04/14/23 | USD | 81.00 | USD | 2,448 | (72,422 | ) | ||||||||||||||||||||
Intuitive Surgical, Inc. | 72 | 04/14/23 | USD | 245.00 | USD | 1,839 | (90,000 | ) | ||||||||||||||||||||
McKesson Corp. | 39 | 04/14/23 | USD | 350.00 | USD | 1,389 | (38,025 | ) | ||||||||||||||||||||
Pfizer, Inc. | 83 | 04/14/23 | USD | 41.00 | USD | 339 | (4,773 | ) | ||||||||||||||||||||
Thermo Fisher Scientific, Inc. | 89 | 04/14/23 | USD | 560.00 | USD | 5,130 | (176,220 | ) | ||||||||||||||||||||
Vertex Pharmaceuticals, Inc. | 40 | 04/14/23 | USD | 300.00 | USD | 1,260 | (67,600 | ) | ||||||||||||||||||||
Cerevel Therapeutics Holdings, Inc. | 32 | 04/17/23 | USD | 37.38 | USD | 78 | (102 | ) |
3 |
|
Schedule of Investments (unaudited) (continued) March 31, 2023 | BlackRock Health Sciences Trust (BME) |
Exchange-Traded Options Written (continued)
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||||||
Call (continued) | ||||||||||||||||||||||||||||
10X Genomics, Inc., Class A | 15 | 04/21/23 | USD | 50.00 | USD | 84 | $ | (10,425 | ) | |||||||||||||||||||
Agilent Technologies, Inc. | 94 | 04/21/23 | USD | 159.00 | USD | 1,300 | (617 | ) | ||||||||||||||||||||
Alcon, Inc. | 66 | 04/21/23 | USD | 75.00 | USD | 466 | (3,960 | ) | ||||||||||||||||||||
Alkermes PLC | 22 | 04/21/23 | USD | 29.00 | USD | 62 | (880 | ) | ||||||||||||||||||||
Alnylam Pharmaceuticals, Inc. | 16 | 04/21/23 | USD | 250.00 | USD | 321 | (3,200 | ) | ||||||||||||||||||||
Alnylam Pharmaceuticals, Inc. | 43 | 04/21/23 | USD | 200.00 | USD | 861 | (38,270 | ) | ||||||||||||||||||||
AmerisourceBergen Corp. | 23 | 04/21/23 | USD | 160.00 | USD | 368 | (7,302 | ) | ||||||||||||||||||||
AmerisourceBergen Corp. | 81 | 04/21/23 | USD | 157.50 | USD | 1,297 | (38,070 | ) | ||||||||||||||||||||
Amgen, Inc. | 129 | 04/21/23 | USD | 245.00 | USD | 3,119 | (39,990 | ) | ||||||||||||||||||||
Apellis Pharmaceuticals, Inc. | 44 | 04/21/23 | USD | 65.00 | USD | 290 | (16,060 | ) | ||||||||||||||||||||
Arcutis Biotherapeutics, Inc. | 162 | 04/21/23 | USD | 12.50 | USD | 178 | (5,670 | ) | ||||||||||||||||||||
Argenx SE, ADR | 27 | 04/21/23 | USD | 400.00 | USD | 1,006 | (10,057 | ) | ||||||||||||||||||||
Arvinas, Inc. | 26 | 04/21/23 | USD | 40.00 | USD | 71 | (12,480 | ) | ||||||||||||||||||||
Avantor, Inc. | 75 | 04/21/23 | USD | 25.29 | USD | 159 | (245 | ) | ||||||||||||||||||||
BioMarin Pharmaceutical, Inc. | 52 | 04/21/23 | USD | 115.00 | USD | 506 | (3,640 | ) | ||||||||||||||||||||
Boston Scientific Corp. | 111 | 04/21/23 | USD | 47.74 | USD | 555 | (30,034 | ) | ||||||||||||||||||||
Boston Scientific Corp. | 767 | 04/21/23 | USD | 49.00 | USD | 3,837 | (118,885 | ) | ||||||||||||||||||||
Catalent, Inc. | 38 | 04/21/23 | USD | 75.00 | USD | 250 | (5,415 | ) | ||||||||||||||||||||
Cooper Cos., Inc. | 18 | 04/21/23 | USD | 350.00 | USD | 672 | (46,710 | ) | ||||||||||||||||||||
Danaher Corp. | 134 | 04/21/23 | USD | 260.00 | USD | 3,377 | (32,495 | ) | ||||||||||||||||||||
Design Therapeutics, Inc. | 26 | 04/21/23 | USD | 10.00 | USD | 15 | (520 | ) | ||||||||||||||||||||
Dexcom, Inc. | 109 | 04/21/23 | USD | 120.00 | USD | 1,266 | (24,252 | ) | ||||||||||||||||||||
Edwards Lifesciences Corp. | 47 | 04/21/23 | USD | 83.52 | USD | 389 | (8,138 | ) | ||||||||||||||||||||
Encompass Health Corp. | 156 | 04/21/23 | USD | 65.00 | USD | 844 | (5,460 | ) | ||||||||||||||||||||
Envista Holdings Corp. | 80 | 04/21/23 | USD | 39.00 | USD | 327 | (23,200 | ) | ||||||||||||||||||||
Exact Sciences Corp. | 27 | 04/21/23 | USD | 72.50 | USD | 183 | (2,970 | ) | ||||||||||||||||||||
Gilead Sciences, Inc. | 182 | 04/21/23 | USD | 82.00 | USD | 1,510 | (41,223 | ) | ||||||||||||||||||||
Glaukos Corp. | 9 | 04/21/23 | USD | 52.50 | USD | 45 | (1,103 | ) | ||||||||||||||||||||
HCA Healthcare, Inc. | 30 | 04/21/23 | USD | 265.00 | USD | 791 | (25,950 | ) | ||||||||||||||||||||
Hologic, Inc. | 21 | 04/21/23 | USD | 80.00 | USD | 169 | (4,305 | ) | ||||||||||||||||||||
Horizon Therapeutics PLC | 28 | 04/21/23 | USD | 110.00 | USD | 306 | (1,750 | ) | ||||||||||||||||||||
Humana, Inc. | 32 | 04/21/23 | USD | 515.00 | USD | 1,553 | (7,600 | ) | ||||||||||||||||||||
Icon PLC | 31 | 04/21/23 | USD | 240.00 | USD | 662 | (7,750 | ) | ||||||||||||||||||||
Illumina, Inc. | 48 | 04/21/23 | USD | 230.00 | USD | 1,116 | (53,040 | ) | ||||||||||||||||||||
Immunocore Holdings PLC, ADR | 36 | 04/21/23 | USD | 70.00 | USD | 178 | (3,060 | ) | ||||||||||||||||||||
Incyte Corp. | 102 | 04/21/23 | USD | 82.50 | USD | 737 | (510 | ) | ||||||||||||||||||||
Insulet Corp. | 14 | 04/21/23 | USD | 320.00 | USD | 447 | (12,810 | ) | ||||||||||||||||||||
Insulet Corp. | 6 | 04/21/23 | USD | 312.52 | USD | 191 | (8,516 | ) | ||||||||||||||||||||
Ionis Pharmaceuticals, Inc. | 41 | 04/21/23 | USD | 40.00 | USD | 147 | (205 | ) | ||||||||||||||||||||
IQVIA Holdings, Inc. | 69 | 04/21/23 | USD | 220.00 | USD | 1,372 | (2,243 | ) | ||||||||||||||||||||
iRhythm Technologies, Inc. | 4 | 04/21/23 | USD | 120.00 | USD | 50 | (3,220 | ) | ||||||||||||||||||||
Johnson & Johnson | 110 | 04/21/23 | USD | 170.00 | USD | 1,705 | (605 | ) | ||||||||||||||||||||
Krystal Biotech, Inc. | 6 | 04/21/23 | USD | 85.00 | USD | 48 | (2,520 | ) | ||||||||||||||||||||
Legend Biotech Corp., ADR | 27 | 04/21/23 | USD | 50.00 | USD | 130 | (2,160 | ) | ||||||||||||||||||||
Masimo Corp. | 17 | 04/21/23 | USD | 165.00 | USD | 314 | (36,465 | ) | ||||||||||||||||||||
Medtronic PLC | 126 | 04/21/23 | USD | 87.50 | USD | 1,016 | (882 | ) | ||||||||||||||||||||
Medtronic PLC | 44 | 04/21/23 | USD | 82.00 | USD | 355 | (4,444 | ) | ||||||||||||||||||||
Merck & Co., Inc. | 209 | 04/21/23 | USD | 115.00 | USD | 2,224 | (2,195 | ) | ||||||||||||||||||||
Mettler-Toledo International, Inc. | 4 | 04/21/23 | USD | 1,610.00 | USD | 612 | (3,800 | ) | ||||||||||||||||||||
Moderna, Inc. | 23 | 04/21/23 | USD | 190.00 | USD | 353 | (633 | ) | ||||||||||||||||||||
Novocure Ltd. | 51 | 04/21/23 | USD | 100.00 | USD | 307 | (3,570 | ) | ||||||||||||||||||||
Novocure Ltd. | 54 | 04/21/23 | USD | 75.00 | USD | 325 | (2,970 | ) | ||||||||||||||||||||
Omnicell, Inc. | 12 | 04/21/23 | USD | 60.00 | USD | 70 | (3,960 | ) | ||||||||||||||||||||
Penumbra, Inc. | 81 | 04/21/23 | USD | 270.00 | USD | 2,257 | (122,715 | ) | ||||||||||||||||||||
Prometheus Biosciences, Inc. | 13 | 04/21/23 | USD | 145.00 | USD | 140 | (4,550 | ) | ||||||||||||||||||||
PTC Therapeutics, Inc. | 24 | 04/21/23 | USD | 48.00 | USD | 116 | (8,580 | ) | ||||||||||||||||||||
QIAGEN NV | 74 | 04/21/23 | USD | 50.00 | USD | 340 | (14,800 | ) | ||||||||||||||||||||
Quest Diagnostics, Inc. | 156 | 04/21/23 | USD | 140.00 | USD | 2,207 | (50,700 | ) | ||||||||||||||||||||
Regeneron Pharmaceuticals, Inc. | 21 | 04/21/23 | USD | 785.00 | USD | 1,726 | (92,715 | ) | ||||||||||||||||||||
ResMed, Inc. | 33 | 04/21/23 | USD | 220.00 | USD | 723 | (14,850 | ) | ||||||||||||||||||||
Revolution Medicines, Inc. | 35 | 04/21/23 | USD | 30.10 | USD | 76 | (188 | ) | ||||||||||||||||||||
Rhythm Pharmaceuticals, Inc. | 83 | 04/21/23 | USD | 30.00 | USD | 148 | (1,453 | ) |
SCHEDULE OF INVESTMENTS | 4 |
Schedule of Investments (unaudited) (continued) March 31, 2023 | BlackRock Health Sciences Trust (BME) |
Exchange-Traded Options Written (continued)
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||||||
Call (continued) | ||||||||||||||||||||||||||||
Rocket Pharmaceuticals, Inc. | 65 | 04/21/23 | USD | 22.50 | USD | 111 | $ | (975 | ) | |||||||||||||||||||
Sage Therapeutics, Inc. | 20 | 04/21/23 | USD | 47.50 | USD | 84 | (1,050 | ) | ||||||||||||||||||||
Sarepta Therapeutics, Inc. | 9 | 04/21/23 | USD | 150.00 | USD | 124 | (1,665 | ) | ||||||||||||||||||||
STERIS PLC | 31 | 04/21/23 | USD | 200.00 | USD | 593 | (8,447 | ) | ||||||||||||||||||||
STERIS PLC | 5 | 04/21/23 | USD | 185.00 | USD | 96 | (4,550 | ) | ||||||||||||||||||||
Stryker Corp. | 14 | 04/21/23 | USD | 270.00 | USD | 400 | (23,450 | ) | ||||||||||||||||||||
Thermo Fisher Scientific, Inc. | 101 | 04/21/23 | USD | 570.00 | USD | 5,821 | (167,660 | ) | ||||||||||||||||||||
Ultragenyx Pharmaceutical, Inc. | 23 | 04/21/23 | USD | 50.00 | USD | 92 | (1,093 | ) | ||||||||||||||||||||
UnitedHealth Group, Inc. | 75 | 04/21/23 | USD | 495.00 | USD | 3,544 | (25,875 | ) | ||||||||||||||||||||
Vertex Pharmaceuticals, Inc. | 69 | 04/21/23 | USD | 315.00 | USD | 2,174 | (51,750 | ) | ||||||||||||||||||||
Waters Corp. | 40 | 04/21/23 | USD | 340.00 | USD | 1,239 | (6,600 | ) | ||||||||||||||||||||
West Pharmaceutical Services, Inc. | 10 | 04/21/23 | USD | 320.00 | USD | 346 | (28,350 | ) | ||||||||||||||||||||
Zimmer Biomet Holdings, Inc. | 28 | 04/21/23 | USD | 128.33 | USD | 362 | (8,031 | ) | ||||||||||||||||||||
Zoetis, Inc. | 138 | 04/21/23 | USD | 172.00 | USD | 2,297 | (16,206 | ) | ||||||||||||||||||||
Zoetis, Inc. | 166 | 04/27/23 | USD | 167.00 | USD | 2,763 | (82,039 | ) | ||||||||||||||||||||
Abbott Laboratories | 15 | 04/28/23 | USD | 100.00 | USD | 152 | (4,988 | ) | ||||||||||||||||||||
AbbVie, Inc. | 118 | 04/28/23 | USD | 155.00 | USD | 1,881 | (73,160 | ) | ||||||||||||||||||||
Align Technology, Inc. | 15 | 04/28/23 | USD | 330.00 | USD | 501 | (32,475 | ) | ||||||||||||||||||||
AmerisourceBergen Corp. | 23 | 04/28/23 | USD | 155.00 | USD | 368 | (15,870 | ) | ||||||||||||||||||||
AmerisourceBergen Corp. | 81 | 04/28/23 | USD | 160.00 | USD | 1,297 | (24,907 | ) | ||||||||||||||||||||
Baxter International, Inc. | 194 | 04/28/23 | USD | 41.00 | USD | 787 | (28,615 | ) | ||||||||||||||||||||
Becton Dickinson and Co. | 105 | 04/28/23 | USD | 245.00 | USD | 2,599 | (67,200 | ) | ||||||||||||||||||||
Biogen, Inc. | 80 | 04/28/23 | USD | 275.00 | USD | 2,224 | (101,600 | ) | ||||||||||||||||||||
Bristol-Myers Squibb Co. | 74 | 04/28/23 | USD | 69.00 | USD | 513 | (11,248 | ) | ||||||||||||||||||||
Elevance Health, Inc. | 61 | 04/28/23 | USD | 480.00 | USD | 2,805 | (30,042 | ) | ||||||||||||||||||||
Eli Lilly & Co. | 139 | 04/28/23 | USD | 345.00 | USD | 4,774 | (148,730 | ) | ||||||||||||||||||||
Gilead Sciences, Inc. | 141 | 04/28/23 | USD | 81.00 | USD | 1,170 | (44,274 | ) | ||||||||||||||||||||
Intuitive Surgical, Inc. | 38 | 04/28/23 | USD | 265.00 | USD | 971 | (22,610 | ) | ||||||||||||||||||||
McKesson Corp. | 22 | 04/28/23 | USD | 350.00 | USD | 783 | (27,170 | ) | ||||||||||||||||||||
Medtronic PLC | 53 | 04/28/23 | USD | 78.00 | USD | 427 | (17,278 | ) | ||||||||||||||||||||
Medtronic PLC | 85 | 04/28/23 | USD | 82.00 | USD | 685 | (12,622 | ) | ||||||||||||||||||||
Merck & Co., Inc. | 244 | 04/28/23 | USD | 109.00 | USD | 2,596 | (43,188 | ) | ||||||||||||||||||||
Moderna, Inc. | 21 | 04/28/23 | USD | 155.00 | USD | 323 | (16,222 | ) | ||||||||||||||||||||
Moderna, Inc. | 5 | 04/28/23 | USD | 170.00 | USD | 77 | (1,240 | ) | ||||||||||||||||||||
Pfizer, Inc. | 275 | 04/28/23 | USD | 42.00 | USD | 1,122 | (12,100 | ) | ||||||||||||||||||||
Regeneron Pharmaceuticals, Inc. | 20 | 04/28/23 | USD | 790.00 | USD | 1,643 | (86,500 | ) | ||||||||||||||||||||
Sarepta Therapeutics, Inc. | 62 | 04/28/23 | USD | 141.00 | USD | 855 | (35,030 | ) | ||||||||||||||||||||
UnitedHealth Group, Inc. | 209 | 04/28/23 | USD | 485.00 | USD | 9,877 | (173,470 | ) | ||||||||||||||||||||
Vertex Pharmaceuticals, Inc. | 70 | 04/28/23 | USD | 315.00 | USD | 2,205 | (65,800 | ) | ||||||||||||||||||||
Alcon, Inc. | 136 | 05/01/23 | USD | 68.50 | USD | 959 | (52,767 | ) | ||||||||||||||||||||
Abbott Laboratories | 231 | 05/05/23 | USD | 101.00 | USD | 2,339 | (69,300 | ) | ||||||||||||||||||||
AbbVie, Inc. | 101 | 05/05/23 | USD | 160.00 | USD | 1,610 | (37,117 | ) | ||||||||||||||||||||
Baxter International, Inc. | 177 | 05/05/23 | USD | 40.00 | USD | 718 | (40,267 | ) | ||||||||||||||||||||
Cigna Group | 50 | 05/05/23 | USD | 260.00 | USD | 1,278 | (38,500 | ) | ||||||||||||||||||||
Eli Lilly & Co. | 114 | 05/05/23 | USD | 350.00 | USD | 3,915 | (107,445 | ) | ||||||||||||||||||||
Exact Sciences Corp. | 35 | 05/05/23 | USD | 71.00 | USD | 237 | (10,325 | ) | ||||||||||||||||||||
Intuitive Surgical, Inc. | 58 | 05/05/23 | USD | 255.00 | USD | 1,482 | (65,830 | ) | ||||||||||||||||||||
Johnson & Johnson | 96 | 05/05/23 | USD | 160.00 | USD | 1,488 | (20,688 | ) | ||||||||||||||||||||
McKesson Corp. | 32 | 05/05/23 | USD | 365.00 | USD | 1,139 | (18,560 | ) | ||||||||||||||||||||
Medtronic PLC | 75 | 05/05/23 | USD | 83.00 | USD | 605 | (7,800 | ) | ||||||||||||||||||||
Merck & Co., Inc. | 210 | 05/05/23 | USD | 108.00 | USD | 2,234 | (52,710 | ) | ||||||||||||||||||||
Pfizer, Inc. | 427 | 05/05/23 | USD | 42.00 | USD | 1,742 | (29,676 | ) | ||||||||||||||||||||
Bausch & Lomb Corp. | 80 | 05/09/23 | USD | 17.50 | USD | 139 | (7,236 | ) | ||||||||||||||||||||
AmerisourceBergen Corp. | 3 | 05/12/23 | USD | 165.00 | USD | 48 | (788 | ) | ||||||||||||||||||||
BioMarin Pharmaceutical, Inc. | 80 | 05/12/23 | USD | 96.50 | USD | 778 | (40,647 | ) | ||||||||||||||||||||
Regeneron Pharmaceuticals, Inc. | 26 | 05/12/23 | USD | 840.00 | USD | 2,136 | (58,370 | ) | ||||||||||||||||||||
10X Genomics, Inc., Class A | 22 | 05/19/23 | USD | 55.00 | USD | 123 | (12,100 | ) | ||||||||||||||||||||
AbbVie, Inc. | 100 | 05/19/23 | USD | 160.00 | USD | 1,594 | (44,250 | ) | ||||||||||||||||||||
Agilent Technologies, Inc. | 63 | 05/19/23 | USD | 150.00 | USD | 872 | (8,820 | ) | ||||||||||||||||||||
Alcon, Inc. | 136 | 05/19/23 | USD | 70.00 | USD | 959 | (46,580 | ) | ||||||||||||||||||||
Alkermes PLC | 19 | 05/19/23 | USD | 29.00 | USD | 54 | (2,043 | ) | ||||||||||||||||||||
Arvinas, Inc. | 15 | 05/19/23 | USD | 31.65 | USD | 41 | (2,562 | ) |
5 |
|
Schedule of Investments (unaudited) (continued) March 31, 2023 | BlackRock Health Sciences Trust (BME) |
Exchange-Traded Options Written (continued)
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||||||
Call (continued) | ||||||||||||||||||||||||||||
Avantor, Inc. | 149 | 05/19/23 | USD | 22.50 | USD | 315 | $ | (10,430 | ) | |||||||||||||||||||
Bausch & Lomb Corp. | 55 | 05/19/23 | USD | 17.50 | USD | 96 | (5,913 | ) | ||||||||||||||||||||
Blueprint Medicines Corp. | 50 | 05/19/23 | USD | 50.00 | USD | 225 | (13,125 | ) | ||||||||||||||||||||
Boston Scientific Corp. | 767 | 05/19/23 | USD | 49.00 | USD | 3,837 | (185,997 | ) | ||||||||||||||||||||
Catalent, Inc. | 38 | 05/19/23 | USD | 70.50 | USD | 250 | (20,284 | ) | ||||||||||||||||||||
Cerevel Therapeutics Holdings, Inc. | 31 | 05/19/23 | USD | 25.00 | USD | 76 | (5,813 | ) | ||||||||||||||||||||
Cooper Cos., Inc. | 31 | 05/19/23 | USD | 370.00 | USD | 1,157 | (52,855 | ) | ||||||||||||||||||||
Dexcom, Inc. | 99 | 05/19/23 | USD | 125.00 | USD | 1,150 | (39,600 | ) | ||||||||||||||||||||
Edwards Lifesciences Corp. | 42 | 05/19/23 | USD | 85.00 | USD | 347 | (13,230 | ) | ||||||||||||||||||||
Genmab A/S, ADR | 64 | 05/19/23 | USD | 40.00 | USD | 242 | (11,360 | ) | ||||||||||||||||||||
Glaukos Corp. | 9 | 05/19/23 | USD | 52.50 | USD | 45 | (2,115 | ) | ||||||||||||||||||||
Hologic, Inc. | 21 | 05/19/23 | USD | 80.01 | USD | 169 | (6,964 | ) | ||||||||||||||||||||
IDEXX Laboratories, Inc. | 27 | 05/19/23 | USD | 510.00 | USD | 1,350 | (59,670 | ) | ||||||||||||||||||||
Insulet Corp. | 12 | 05/19/23 | USD | 340.00 | USD | 383 | (11,160 | ) | ||||||||||||||||||||
Ionis Pharmaceuticals, Inc. | 29 | 05/19/23 | USD | 40.00 | USD | 104 | (1,378 | ) | ||||||||||||||||||||
IQVIA Holdings, Inc. | 30 | 05/19/23 | USD | 210.00 | USD | 597 | (14,100 | ) | ||||||||||||||||||||
iRhythm Technologies, Inc. | 4 | 05/19/23 | USD | 125.00 | USD | 50 | (3,640 | ) | ||||||||||||||||||||
Johnson & Johnson | 161 | 05/19/23 | USD | 160.00 | USD | 2,496 | (35,098 | ) | ||||||||||||||||||||
Karuna Therapeutics, Inc. | 6 | 05/19/23 | USD | 220.00 | USD | 109 | (780 | ) | ||||||||||||||||||||
Krystal Biotech, Inc. | 6 | 05/19/23 | USD | 95.00 | USD | 48 | (1,920 | ) | ||||||||||||||||||||
Legend Biotech Corp., ADR | 26 | 05/19/23 | USD | 55.00 | USD | 125 | (6,565 | ) | ||||||||||||||||||||
Masimo Corp. | 16 | 05/19/23 | USD | 175.00 | USD | 295 | (27,120 | ) | ||||||||||||||||||||
Medtronic PLC | 75 | 05/19/23 | USD | 85.00 | USD | 605 | (7,125 | ) | ||||||||||||||||||||
Omnicell, Inc. | 12 | 05/19/23 | USD | 60.00 | USD | 70 | (4,620 | ) | ||||||||||||||||||||
Prometheus Biosciences, Inc. | 13 | 05/19/23 | USD | 125.00 | USD | 140 | (6,825 | ) | ||||||||||||||||||||
Prothena Corp. PLC | 33 | 05/19/23 | USD | 55.00 | USD | 160 | (5,445 | ) | ||||||||||||||||||||
QIAGEN NV | 43 | 05/19/23 | USD | 50.00 | USD | 197 | (2,903 | ) | ||||||||||||||||||||
Repligen Corp. | 31 | 05/19/23 | USD | 190.00 | USD | 522 | (14,260 | ) | ||||||||||||||||||||
ResMed, Inc. | 21 | 05/19/23 | USD | 220.00 | USD | 460 | (18,795 | ) | ||||||||||||||||||||
Revolution Medicines, Inc. | 18 | 05/19/23 | USD | 25.00 | USD | 39 | (1,260 | ) | ||||||||||||||||||||
Rhythm Pharmaceuticals, Inc. | 32 | 05/19/23 | USD | 20.00 | USD | 57 | (4,160 | ) | ||||||||||||||||||||
Sage Therapeutics, Inc. | 62 | 05/19/23 | USD | 47.50 | USD | 260 | (8,835 | ) | ||||||||||||||||||||
Stryker Corp. | 233 | 05/19/23 | USD | 280.00 | USD | 6,651 | (329,695 | ) | ||||||||||||||||||||
Waters Corp. | 6 | 05/19/23 | USD | 330.00 | USD | 186 | (4,170 | ) | ||||||||||||||||||||
West Pharmaceutical Services, Inc. | 10 | 05/19/23 | USD | 360.00 | USD | 346 | (13,050 | ) | ||||||||||||||||||||
West Pharmaceutical Services, Inc. | 38 | 05/19/23 | USD | 329.00 | USD | 1,317 | (111,866 | ) | ||||||||||||||||||||
Alkermes PLC | 22 | 06/06/23 | USD | 29.12 | USD | 62 | (2,921 | ) | ||||||||||||||||||||
Edwards Lifesciences Corp. | 53 | 06/16/23 | USD | 85.00 | USD | 438 | (20,670 | ) | ||||||||||||||||||||
|
| |||||||||||||||||||||||||||
$ | (5,516,287 | ) | ||||||||||||||||||||||||||
|
|
OTC Options Written
Description | Counterparty | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | ||||||||||||||||||||||||
Call | ||||||||||||||||||||||||||||||
Daiichi Sankyo Co. Ltd. | JPMorgan Chase Bank N.A. | 22,500 | 04/04/23 | JPY | 4,374.24 | JPY | 108,495 | $ | (77,039 | ) | ||||||||||||||||||||
Bausch & Lomb Corp. | UBS AG | 8,000 | 04/05/23 | USD | 17.25 | USD | 139 | (3,382 | ) | |||||||||||||||||||||
Genmab A/S | Morgan Stanley & Co. International PLC | 900 | 04/05/23 | DKK | 2,707.91 | DKK | 2,330 | (263 | ) | |||||||||||||||||||||
Novo Nordisk A/S, Class B | Morgan Stanley & Co. International PLC | 5,000 | 04/05/23 | DKK | 1,016.12 | DKK | 5,429 | (51,054 | ) | |||||||||||||||||||||
Sanofi | Morgan Stanley & Co. International PLC | 4,700 | 04/05/23 | EUR | 90.47 | EUR | 471 | (49,992 | ) | |||||||||||||||||||||
Neurocrine Biosciences, Inc. | Barclays Bank PLC | 4,400 | 04/11/23 | USD | 107.00 | USD | 445 | (1,462 | ) | |||||||||||||||||||||
Roche Holding AG | Morgan Stanley & Co. International PLC | 1,300 | 04/11/23 | CHF | 288.68 | CHF | 339 | (10 | ) | |||||||||||||||||||||
Daiichi Sankyo Co. Ltd. | BNP Paribas SA | 10,500 | 04/13/23 | JPY | 4,411.49 | JPY | 50,631 | (36,864 | ) | |||||||||||||||||||||
Bausch & Lomb Corp. | JPMorgan Chase Bank N.A. | 7,300 | 04/24/23 | USD | 18.35 | USD | 127 | (2,671 | ) | |||||||||||||||||||||
Novo Nordisk A/S, Class B | UBS AG | 5,000 | 04/26/23 | DKK | 1,026.80 | DKK | 5,429 | (49,310 | ) | |||||||||||||||||||||
Sanofi | JPMorgan Chase Bank N.A. | 4,700 | 04/27/23 | EUR | 91.74 | EUR | 471 | (46,230 | ) | |||||||||||||||||||||
Zimmer Biomet Holdings, Inc. | Citibank N.A. | 2,700 | 04/27/23 | USD | 126.96 | USD | 349 | (12,425 | ) | |||||||||||||||||||||
Daiichi Sankyo Co. Ltd. | Citibank N.A. | 10,400 | 05/02/23 | JPY | 4,526.08 | JPY | 50,149 | (32,367 | ) | |||||||||||||||||||||
Rhythm Pharmaceuticals, Inc. | Barclays Bank PLC | 6,700 | 05/04/23 | USD | 28.00 | USD | 120 | (1,496 | ) | |||||||||||||||||||||
Alkermes PLC | JPMorgan Chase Bank N.A. | 5,900 | 05/08/23 | USD | 27.31 | USD | 166 | (10,821 | ) |
SCHEDULE OF INVESTMENTS | 6 |
Schedule of Investments (unaudited) (continued) March 31, 2023 | BlackRock Health Sciences Trust (BME) |
OTC Options Written (continued)
Description | Counterparty | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | ||||||||||||||||||||||||
Call (continued) | ||||||||||||||||||||||||||||||
AstraZeneca PLC | Goldman Sachs International | 8,900 | 05/10/23 | GBP | 114.08 | GBP | 1,000 | $ | (28,718 | ) | ||||||||||||||||||||
Neurocrine Biosciences, Inc. | Barclays Bank PLC | 4,400 | 05/15/23 | USD | 100.47 | USD | 445 | (19,772 | ) | |||||||||||||||||||||
Roche Holding AG | UBS AG | 1,200 | 05/16/23 | CHF | 258.83 | CHF | 313 | (9,183 | ) | |||||||||||||||||||||
AstraZeneca PLC | Goldman Sachs International | 6,700 | 05/18/23 | GBP | 114.83 | GBP | 753 | (21,887 | ) | |||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
$ | (454,946 | ) | ||||||||||||||||||||||||||||
|
|
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:
• | Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access; |
• | Level 2 – Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market–corroborated inputs); and |
• | Level 3 – Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Valuation Committee’s assumptions used in determining the fair value of financial instruments). |
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds. There may not be a secondary market, and/or there are a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust’s policy regarding valuation of financial instruments, refer to its most recent financial statements.
Certain investments of the Trust were fair valued using net asset value (“NAV”) as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.
| ||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| ||||||||||||||||
Assets | ||||||||||||||||
Investments | ||||||||||||||||
Long-Term Investments | ||||||||||||||||
Common Stocks | ||||||||||||||||
Biotechnology | $ | 127,434,326 | $ | 944,257 | $ | 257,586 | $ | 128,636,169 | ||||||||
Health Care Equipment & Supplies | 146,750,542 | — | — | 146,750,542 | ||||||||||||
Health Care Providers & Services | 88,096,745 | — | — | 88,096,745 | ||||||||||||
Life Sciences Tools & Services | 77,818,709 | — | — | 77,818,709 | ||||||||||||
Pharmaceuticals | 103,085,941 | 18,295,645 | — | 121,381,586 | ||||||||||||
Other Interests | — | — | 150,226 | 150,226 | ||||||||||||
Preferred Securities | ||||||||||||||||
Preferred Stocks | — | — | 4,098,826 | 4,098,826 | ||||||||||||
Rights | — | — | 40,062 | 40,062 | ||||||||||||
Warrants | 2,622 | — | — | 2,622 | ||||||||||||
Short-Term Securities | ||||||||||||||||
Money Market Funds | 20,478,474 | — | — | 20,478,474 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
$ | 563,667,359 | $ | 19,239,902 | $ | 4,546,700 | 587,453,961 | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Investments Valued at NAV(a) | 3,860,355 | |||||||||||||||
|
| |||||||||||||||
$ | 591,314,316 | |||||||||||||||
|
|
7 |
|
Schedule of Investments (unaudited) (continued) March 31, 2023 | BlackRock Health Sciences Trust (BME) |
Fair Value Hierarchy as of Period End (continued)
| ||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| ||||||||||||||||
Derivative Financial Instruments(b) | ||||||||||||||||
Liabilities | ||||||||||||||||
Equity Contracts | $ | (5,116,924 | ) | $ | (854,309 | ) | $ | — | $ | (5,971,233 | ) | |||||
|
|
|
|
|
|
|
|
(a) | Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy. |
(b) | Derivative financial instruments are options written. Options written are shown at value. |
Currency Abbreviation | ||
CHF | Swiss Franc | |
DKK | Danish Krone | |
EUR | Euro | |
GBP | British Pound | |
JPY | Japanese Yen | |
USD | United States Dollar |
Portfolio Abbreviation | ||
ADR | American Depositary Receipt |
SCHEDULE OF INVESTMENTS | 8 |